Following the announcement in November 2011 that leading pharmaceutical manufacturer, Aesica, opened a new purpose built $4.6 million high potency manufacturing facility for the manufacture of formulated products, the company has confirmed plans to upgrade its Active Pharmaceutical Ingredient manufacturing facilities, enabling it to manufacture high potency APIs at commercial scale.
The upgrade will ensure Aesica can manufacture SafeBridge® Category 3 API and formulated products from pilot to commercial scale from two of its sites in Europe. The ability to offer high potency manufacturing on a larger scale is particularly important for the company’s further growth in the API arena, as Aesica will be able to offer high containment from the kilo lab to the pilot plant and through to full commercial scale production.
The new facilities will enable Aesica to successfully manage high potency API production at quantities from 1kg to 200kg. Further investment in API manufacturing capability in 2013 will equip Aesica to produce batch sizes up to 600kg.
Dr. Robert Hardy, Chief Executive, Aesica, said:
“The evolution of drug development and the increasing potency of compounds has meant that more customers are looking to outsource high containment drug manufacturing. We predict our new high containment Formulated Product facility and this latest investment in high potency API production will play a pivotal role in increasing our share of the contract manufacturing market. Opening our new high containment facility for the manufacture of formulated products last year showed that we are extremely committed to this increasingly important marketplace and it was a natural progression to broaden our offering around high potency APIs. When it comes to high potency drugs, we are a leader among UK CMOs and the new facility demonstrates our desire to become the name in high containment manufacturing.”
Aesica is a leading full-service provider of development and manufacturing services for Formulated Products and Active Pharmaceutical Ingredients. The company develops long-term strategic partnerships with its clients to help them deliver value into the market place.
Its long-term vision is to be the number one supplier of Active Pharmaceutical Ingredients and Formulated Products to the pharmaceutical industry and Aesica has always believed that this vision will be achieved through a combination of organic growth and strategic acquisitions.